Genelux (GNLX) said Tuesday that during a review of the approval pathway for Olvi-Vec in platinum-resistant ovarian cancer, the US Food and Drug Administration recommended conducting an interim overall survival analysis alongside the primary progression-free survival analysis
The company said the agency indicated that data from the ongoing phase 3 trial could support traditional approval if it shows a "clinically meaningful" progression-free survival benefit without a decline in overall survival.
Genelux said the FDA suggested the company request a pre-Biologics License Application meeting after topline safety and efficacy results are available. Genelux said it expects to report these results in H1 2026.
Shares of the company fell 14% in recent Tuesday trading.
Price: 3.29, Change: -0.60, Percent Change: -15.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.